Antares Pharma (Antares Pharma) EBIT per Share : $0.33 (TTM As of Mar. 2022)

View and export this data going back to 1996. Start your Free Trial

What is Antares Pharma EBIT per Share?

Antares Pharma's EBIT per Share for the three months ended in Mar. 2022 was $-0.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2022 was $0.33.

During the past 12 months, the average EBIT per Share Growth Rate of Antares Pharma was -9.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Antares Pharma's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Antares Pharma was 42.10% per year. The lowest was -80.20% per year. And the median was 8.35% per year.

ATRS's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 6.75
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Antares Pharma's EBIT for the three months ended in Mar. 2022 was $-3.0 Mil.

Antares Pharma EBIT per Share Historical Data

The historical data trend for Antares Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma EBIT per Share Chart

Antares Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT per Share

Get a 7-Day Free Trial

-0.10

-0.02

0.01

0.08

0.38

Antares Pharma Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
EBIT per Share	Get a 7-Day Free Trial															0.03	0.04	0.05	0.26	-0.02

Antares Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Antares Pharma's EBIT per Share for the fiscal year that ended in Dec. 2021 is calculated as

	EBIT per Share		(A: Dec. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	65.882	/	174.733
=	0.38

Antares Pharma's EBIT per Share for the quarter that ended in Mar. 2022 is calculated as

	EBIT per Share		(Q: Mar. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.964	/	170.104
=	-0.02

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.33

Antares Pharma (NAS:ATRS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Antares Pharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Antares Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Antares Pharma (Antares Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Antares Pharma Inc (NAS:ATRS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Princeton South, Suite 300, Ewing, NJ, USA, 08628

Website

https://www.antarespharma.com

Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.

Executives

Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Carmen B Volkart	director	C/O MODULAR MEDICAL, INC., 16772 WEST BERNARDO DRIVE, SAN DIEGO CA 92127
Peter C Richardson	officer: See Remarks	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Fred M Powell	officer: Executive Vice President & CFO	C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Thomas J Garrity	director
Roche Robert P Jr	director	41 MOORES ROAD FRAZER PA 19355
Leonard S Jacob	director	C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Peter J Graham	officer: See Remarks	315 E. 72ND ST., APT 5E, NEW YORK NY 10021
Peter Greenleaf	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anton Gueth	director
Robert F Apple	director, officer: President & CEO	C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Marvin Samson	director
Jacques Gonella	director	C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
James Patrick Tursi	officer: EVP, Chief Medical Officer	106 ASHLEY COURT, MOORESTOWN NJ 08057
Keith E Muckenhirn	officer: VP/Controller & Interim CFO	C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447